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Alzheimer’sdisease(AD)isanage-associatedneurodegenerativediseasecharacterizedbytheprogressivelossofcognitivefunction,
loss of memory and insomnia, and abnormal behavioral signs and symptoms. Among the various theories that have been put
forth to explain the pathophysiology of AD, the oxidative stress induced by amyloid β-protein (Aβ) deposition has received great
attention. Studies undertaken on postmortem brain samples of AD patients have consistently shown extensive lipid, protein, and
DNA oxidation. Presence of abnormal tau protein, mitochondrial dysfunction, and protein hyperphosphorylation all have been
demonstrated in neural tissues of AD patients. Moreover, AD patients exhibit severe sleep/wake disturbances and insomnia and
these are associated with more rapid cognitive decline and memory impairment. On this basis, the successful management of AD
patients requires an ideal drug that besides antagonizing Aβ-induced neurotoxicity could also correct the disturbed sleep-wake
rhythm and improve sleep quality. Melatonin is an eﬀective chronobiotic agent and has signiﬁcant neuroprotective properties
preventing Aβ-induced neurotoxic eﬀects in a number of animal experimental models. Since melatonin levels in AD patients are
greatly reduced, melatonin replacement has the potential value to be used as a therapeutic agent for treating AD, particularly at
the early phases of the disease and especially in those in whom the relevant melatonin receptors are intact. As sleep deprivation
has been shown to produce oxidative damage, impaired mitochondrial function, neurodegenerative inﬂammation, and altered
proteosomal processing with abnormal activation of enzymes, treatment of sleep disturbances may be a priority for arresting the
progression of AD. In this context the newly introduced melatonin agonist ramelteon can be of much therapeutic value because of
its highly selective action on melatonin MT1/MT2 receptors in promoting sleep.
1.Introduction
Alzheimer’s disease (AD), a major age-associated neurode-
generative disease, is characterized by progressive loss of cog-
nitive function, loss of memory, impaired synaptic function,
and a massive brain cell loss that ultimately results in prema-
ture death. Although the exact cause of the disease is under
intense investigation, the prevailing hypothesis proposes that
the deposition of amyloid β-protein- (Aβ-)containing senile
plaques and of intracellular neuroﬁbrillary tangles major
etiological factors in AD [1]. Deposition of amyloid plaques
causes cell death by inducing mitochondrial dysfunction
and oxidative stress [2]. Aβ deposition initiates the ﬂavo-
enzyme-dependent increase of hydrogen peroxide (H2O2)
and lipid peroxides that increase free radical generation
[3, 4]. Neural tissues of AD patients exhibit increased levels2 International Journal of Alzheimer’s Disease
of end products of peroxidation such as malondialdehyde,
4-hydroxynonenal, or carbonyls. Though Aβ contributes
directly or indirectly to neuronal degeneration, its potential
to cause AD depends on individual’s susceptibility to Aβ-
mediated toxicity [5].
Mitochondrial dysfunction plays an important role in
AD and the link among impaired mitochondrial function,
tau phosphorylation, and Aβ amyloidosis is increasingly
recognized as a major phenomenon in AD physiopathology
[2, 6, 7]. Aβ accumulation and neuroﬁbrillary tangles
composed of tau protein induce functional deﬁcits of the
respiratory chain complexes thereby resulting in mitochon-
drial dysfunction and oxidative stress (the “Aβ cascade
hypothesis of AD”). It is interesting to note that women are
more vulnerable to AD than men, presumably because the
mitochondria are protected by estrogens against Aβ toxicity
[8].
Indeed, aging and neurodegenerative diseases are accom-
panied by abnormal levels of oxidation of proteins, lipids,
and nucleic acids [9–11]. Mechanisms such as chronic
inﬂammation associated with the release of cytokines and
trace element neurotoxicity have also been suggested as pos-
sible contributory factors underlying the physiopathologic
events of AD [12–14]. Membrane disruption and induction
of apoptosis by caspase enzymes have also been implicated
[15].
In addition to cognitive and memory dysfunction, sleep-
wake and other circadian rhythm dysregulation, are com-
m o n l ys e e ni nA D[ 16–19]. These circadian rhythm distur-
bances are associated with disturbed melatonin rhythmicity
and decreased circulating and brain melatonin levels [20–
22]. It is hypothesized that the decreased levels of melatonin,
in fact, could contribute to the pathophysiology of AD in
view than melatonin combines chronobiotic with eﬀective
antioxidant, anti-inﬂammatory, and antiﬁbrillogenic prop-
erties [23].
Among the factors known to suppress the production
of melatonin by the pineal gland, hypoxia deserves to be
considered [24]. Reduced production of melatonin has been
reported to occur in other ischemic conditions such as
coronaryarterydiseaseorseverecongestiveheartfailure[25–
27]. Hypoxia may play a role in the pathogenesis of AD as it
can induce formation of Aβ [28–30] .T h er o l eo fh y p o x i ai n
potentiatingADissupportedbytheobservationthatpatients
suﬀering from cardiorespiratory disorders, cerebral ischemia
or stroke are much more susceptible to development of
dementias including AD [31]. It is remarkable that the daily
administrationofmelatoninreducesthehypoxiainducedAβ
generation in the rat hippocampus [32].
With this background, the replacement of brain mela-
toninlevelshasbeensuggestedasawayarrestingtheprogress
of AD and for correcting the circadian and sleep-wake
disturbances associated with the disease. As melatonin is
a short-lived molecule having a limited duration of action
(half life = 0.54-0–67h [33]), analogs with a high aﬃnity
for melatonin receptors and a longer duration of action
have been synthesized with a potential therapeutic eﬃcacy
to treat insomnia and psychiatric disorders like depression
and bipolar aﬀective disorder [34]. Ramelteon was the ﬁrst
of these molecules approved by the U.S. Food and Drug
Administration to be used in the treatment of insomnia [35]
and its potential use in AD together with that of melatonin is
discussed in this review article.
2.M elat o nininAD
Melatonin is synthesized both in the pineal gland and in a
number of peripheralorgansand tissuesbyaprocessstarting
with tryptophan conversion to serotonin (reviewed in [36]).
Serotonin is then acetylated to form N-acetylserotonin
by the enzyme arylakylamine N-acetyltransferase while N-
acetylserotonin is converted into melatonin by the enzyme
hydroxyindole-O-methyl transferase [37, 38]. Once formed
melatonin is not stored within the pineal gland it diﬀuses
into the capillary blood and the cerebrospinal ﬂuid (CSF)
[39, 40]. CSF melatonin values are nearly 30 times higher
than those in the blood; thus, the brain tissue has a higher
melatonin concentration than any other tissue in the body
[41].
Regional distribution of melatonin in diﬀerent areas
of the brain varies and early studies have shown that
hypothalamicmelatoninconcentrationsarenearlyﬁftytimes
higher than in plasma [42–44]. While tissue melatonin
only exhibits a moderate circadian variation, circulating
melatonin exhibits most pronounced circadian rhythm with
highest levels occurring at night and very low levels during
daytime [36].
Circulating melatonin is metabolized mainly in the liver
via hydroxylation in the C6 position by cytochrome P450
monooxygenases (CYP1A2;CYP1A1) [45]. It is thereafter
conjugated with sulphate to form 6-sulfatoxymelatonin
(aMT6S), the main metabolite of melatonin in urine. In the
brain, melatonin is metabolized to kynuramine derivatives
like N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK)
[46,47].Inseveraltissuesmelatoninisalsononenzymatically
metabolized to cyclic 3-hydroxy melatonin [48].
Melatoninisinvolvedinthecontrolofvariousphysiolog-
ical functions such as circadian rhythmicity [49, 50], sleep
regulation [51, 52], immune function [53, 54], antioxidant
defense [55, 56], control of reproduction [57–59], inhibition
of tumor growth [60, 61], and control of human mood
[62, 63]. Melatonin participates in many of these functions
by acting through G-protein membrane receptors, the MT1
and MT2 melatonin receptors [64–66]. Nuclear melatonin
receptors belonging to the RZR/ROR α receptor class have
also been described [56, 67, 68]. Melatonin also acts directly
onthecellswithouttheintervention ofanyofthesereceptors
by binding to intracellular proteins like calmodulin [69]
or tubulin [70]. In general, the free radical scavenging
action of melatonin does not involve receptors except for
the induction of synthesis of some antioxidant enzymes
like γ-glutamylcysteine synthase that involves RZR/ROR α
receptors [71].
In view of the involvement of oxidative stress in AD,
melatonin represents an interesting neuroprotective agent as
it antagonizes oxidative stress both in a direct and in an
indirect way [55, 56, 72, 73]. In the N2a murine neurob-
lastoma cell model Pappolla et al. [74] ﬁrst demonstratedInternational Journal of Alzheimer’s Disease 3
thatcoincubationofAβ withmelatoninsigniﬁcantlyreduced
several features of apoptosis like cellular shrinkage or forma-
tion of membrane blubs. In a number of studies melatonin
prevented the death of neuroblastoma cells exposed to Aβ
[5, 75, 76].
Several animal models of AD have been used to study
the possible antoxidative and antiapoptotic actions of mela-
tonin in arresting neuronal lesions. Okadaic acid induces
physiological and biochemical changes similar to those seen
in AD. Increased levels of 4-hydroxynonenal in cultured
neuronal cells have been found following administration of
okadaic acid [77]. After the administration of antioxidants
like melatonin or vitamin C, the eﬀects of okadaic acid
on NIE 115 neuronal cells were prevented eﬀectively [78].
Melatonin was more eﬀective than vitamin C, since it not
only prevented the free radical-induced damage with greater
eﬃciency but also increased the activity of the antioxidant
enzymes glutathione-S transferase and glutathione reductase
[78].
Several studies indicate that the apoptosis of astrocytes
contribute to the pathogenesis of AD (sees [79]). Astrocytes
exhibit tau phosphorylation and activation of stress kinases
as seen in AD pathology. They also produce apolipoprotein
E4 (apoE4) that aggravates Aβ neurodegenerative eﬀects
[80, 81]. During interaction with Aβ,a s t r o c y t e sl o s ec o n t r o l
over NO production leading to the neurotoxic peroxynitrate
formation. By treating the C6 astroglioma cells with mela-
tonin, the increase in NO production induced by Aβ was
eﬀectively prevented [82].
3.MolecularMechanismsof Melatonin’s
Anti-AmyloidActions
Melatonin not only reduced apoptosis but also exerts its
antiamyloid actions through additional mechanisms. One of
them is by preventing Aβ-induced mitochondrial damage
and disruption of respiration. Melatonin administration
prevented Aβ action on mitochondrial DNA proteins and
level of lipid peroxidation [75]. In this aspect it is interesting
to note that melatonin’s metabolite AFMK also oﬀered
protection from Aβ-induced mitochondrial oxidative stress
[83] although a higher concentration was needed.
Melatonin inhibits the formation of amyloid ﬁbrils as
demonstratedbydiﬀerenttechniques[84,85].Thestructural
analog of melatonin indole-3-propionic acid not only shares
the radical scavenging activity of melatonin [86] but also
exhibits similar or even higher antiﬁbrillogenic activity [87].
Several lipoproteins can modulate ﬁbrillogenesis [88].
Melatonin was shown to reverse the proﬁbrillogenic activity
of apoE4 and to antagonize the neurotoxic combinations
of Aβ and apoE4 or apoE3 [83]. ApoE4 is also produced
by astrocytes and aggravates Aβ eﬀects showing thereby
the mutual interaction of Aβ protein and apo-E4 in the
astrocyte-neuron interactions [81]. The antiﬁbrillogenic
eﬀects of melatonin and its metabolites were observed not
only in vitro but also in vivo in transgenic mouse models
[84, 89, 90]. Protection from Aβ toxicity was observed,
especially at the mitochondrial level.
As mentioned above, chronic intermittent hypoxia has
been shown to induce Aβ protein generation by upregulating
the APP processing enzymes BACE and PSEN-1 [28–30].
The daily administration of melatonin (10mg/kg) prior to a
short-term hypoxia prevented the generation of Aβ protein
but it did not reduce the increase of HIF-1 transcription
factor induced by hypoxia [32]. Hence it was suggested that
melatonin’sneuroprotectiveeﬀectagainstamyloid-β-peptide
wasduetoitsdirectfreeradicalscavengingpropertiesactions
[32].
Another manifestation of AD studied in experimental
models is the expression of protein hyperphosphorylation
and cytoskeletal disorganization. Calyculin A, an inhibitor of
protein phosphatases (PP), was used in neuroblastoma N2
cells to examine this point. Calyculin A resulted in activation
of glycogen synthase kinase 3 (GSK-3), a redox-controlled
enzyme involved in various regulatory mechanisms of the
cell, and the consequent hyperphosphorylation of tau [91].
Melatonin administration decreased oxidative stress and
tau hyperphosphorylation and reversed GSK-3 activation
showing thereby that it not only acts as an antioxidant but
also interferes with the phosphorylation system, particularly
stress kinases [91].
The inhibition of PP-2A and PP-1 brought about by
calyculin A caused hyperphosphorylation of tau and of
neuroﬁlaments, synaptophysin loss, and spatial memory
retentionimpairment,aneﬀectcounteractedbytheadminis-
tration of melatonin i.p. for 9 days before calyculin injection
[92]. Melatonin also partially reversed the phosphorylation
of the catalytic subunit of PP-2A at tyrosine 307 (Y307)
crucial site regulating the activity of PP-2A, and reduced
malondialdehyde levels induced by calyculin A [92]. Mela-
tonin also attenuated tau hyperphosphorylation induced by
wortmannin [93, 94] and isoproterenol [95].
Tyrosine kinase (trk) receptors, important elements of
the phosphorylation system, as well as neurotrophins, are
aﬀectedbyAβ and other oxidotoxins and melatonin normal-
ized in neuroblastoma cells trk and neurotrophin expression
[96]. Recent studies using organotypic hippocampal studies
conﬁrmed that the presence of melatonin (25–100μM)
prevented the cell damage induced by exposure to Aβ
reducing the activation of GSK-3β, the phosphorylation of
tau protein, and the Aβ-induced increases of TNF-α and
IL-6 levels [97]. The chronobiological aspects of melatonin-
Aβ interaction are underlined by a study describing the
protective eﬀect of melatonin against the circadian changes
producedbyAβ25–35 microinjectionintothesuprachiasmatic
nuclei (SCN) of golden hamsters [98].
4. PotentialTherapeutic Value of
M elat o nininAD
A number of studies in AD patients have indicated that
thereisaprofounddisturbanceinsleep/wakecycleassociated
with the progression of the disease. Cross-sectional studies
reveal that sleep disturbances are associated with memory
and cognitive impairment. [16–19]. A severe disruption of
the circadian timing system occurs in AD as indicated by4 International Journal of Alzheimer’s Disease
a l t e r a t i o n si nn u m e r o u so v e r tr h y t h m sl i k eb o d yt e m p e r a -
ture, glucocorticoids, and/or plasma melatonin [22, 99, 100].
The internal desynchronization of rhythms is signiﬁcant in
AD patients [101, 102].
“Sundowning” is a chronobiological phenomenon
observed in AD patients in conjunction with sleep-wake
disturbances, including symptoms like disorganized
thinking, reduced ability to maintain attention to external
stimuli, agitation, wandering, and perceptual and emotional
disturbances, all appearing in late afternoon or early evening
[99, 103, 104]. Chronotherapeutic interventions such
as exposure to bright light and/or timed administration
of melatonin in selected circadian phases alleviated
sundowning symptoms like wandering, agitation and
delirium and also improved sleep-wake patterns of AD
patients [105].
A number of studies have revealed that melatonin levels
are lower in AD patients as compared to age-matched
control subjects [20–22, 106]. The decreased CSF melatonin
levels of AD patients were attributed to decreased mela-
tonin production. CSF melatonin levels decreased even in
preclinical stages (Braak stages-1) when patients did not
manifest cognitive impairment [107] suggesting thereby that
reduction in CSF melatonin may be an early marker (and
cause) for incoming AD. The decrease of melatonin levels
in AD was attributed to a defective retinohypothalamic tract
or SCN-pineal connections [108]. The impaired melatonin
production at night correlates signiﬁcantly with the severity
of mental impairment of demented patients [109]. As AD
patients have profound deﬁciency of endogenous melatonin,
replacement of levels of melatonin in the brain could be a
therapeutic strategy for arresting the progress of the disease.
Melatonin’s neuroprotective and vasoprotective properties
would help in enhancing cerebral blood ﬂow and would help
to improve the clinical condition of AD patients [23].
Sleep disturbances exacerbate memory and cognitive
impairment [110]. Therefore, optimization in management
of sleep disturbances is of paramount importance in treating
AD patients. In an initial study on 14 AD patients with 6–
9mg of melatonin given for 2-3 year period it was noted
that melatonin improved sleep quality [111]. Sundowning,
diagnosed clinically, was no longer detectable in 12 out
of 14 patients. Reduction in cognitive impairment and
amnesia was also noted. This should be contrasted with the
signiﬁcant deterioration of the clinical conditions expected
from patients after 1–3 year of evolution of AD [111, 112].
Several studies support the eﬃcacy of melatonin in
treating sleep and chronobiologic disorders in AD patients
(Table 1). The administration of melatonin (6mg/day) for 4
weekstoADpatientsreducednighttimeactivityascompared
to placebo [113]. An improvement of sleep and alleviation
of sundowning were reported in 11AD patients treated
with melatonin (3mg/day at bedtime) and evaluated by
usingactigraphy[114].Improvementinbehavioralsignswas
reported with use of 6–9mg/day of melatonin for 4 months
in AD patients with sleep disturbances [115].
In a double blind study conducted on AD patients
it was noted that 3mg/day of melatonin signiﬁcantly
prolonged actigraphically evaluated sleep time, decreased
activity in night, and improved cognitive functions [119]. In
a multicenter, randomized, placebo-controlled clinical trial
of a sample of 157AD patients with sleep disturbances,
melatonin or placebo was administered for a period of 2
months [120]. In actigraphic studies a trend to increased
nocturnal total sleep time and decreased wake after sleep
onset was noted in the melatonin-treated group. On subjec-
tive measures by caregiver ratings signiﬁcant improvement
in sleep quality was noted with 2.5mg sustained release
melatonin relative to placebo [120].
Negative results with the use of melatonin in fully
developed AD were also published. For example, in a study
in which melatonin (8.5mg fast release and 1.5mg sustained
release) was administered at 10.00PM for 10 consecutive
nights to patients with AD, no signiﬁcant diﬀerence was
noticed with placebo on sleep, circadian rhythms and,
agitation [124]. Although the lack of beneﬁcial eﬀect of
melatonin in this study on sleep could be attributed to the
short period of time examined, it must be noted that large
interindividual diﬀerences between patients suﬀering from a
neurodegenerative disease are not uncommon. It should be
also taken into account that melatonin, though having some
sedating and sleep latency-reducing properties, does not
primarily act as a sleeping pill, but mainly as a chronobiotic.
Since the circadian oscillator system is obviously aﬀected
inADpatientsshowingseveresleepdisturbances,theeﬃcacy
of melatonin should be expected to depend on disease
progression.Inarecentpaperoneofussummarizedthepub-
lished data concerning melatonin treatment of AD patients
[125]( Table 1). Eight reports (5 open-label studies, 2 case
reports) (N = 89 patients) supported a possible eﬃcacy
of melatonin: sleep quality improved and in patients with
AD sundowning was reduced and cognitive decay showed
less progression. In 6 double blind, randomized placebo-
controlled trials (N = 210) sleep was objectively measured
by wrist actigraphy and additionally neuropsychological
assessment and sleep quality were subjectively evaluated.
Sleep quality increased and sundowning decreased signif-
icantly and cognitive performance improved in 4 studies
(N = 143) whereas there was absence of eﬀects in 2
studies (N = 67) [125]. Therefore, the question whether
melatonin has a causal value in preventing or treating
AD, aﬀecting disease progression of the neuropathology
and the driving mechanisms, remains unanswered. Double-
blind multicenter studies are needed to further explore and
investigate the potential and usefulness of melatonin as an
antidementia drug. Its apparent usefulness in symptomatic
treatment, concerning sleep, sundowning, and so forth, even
in a progressed state, further underlines the need for such
decisive studies.
It has been shown that with degeneration of the SCN, the
master body clock, there is a decrease in the expression of
MT1 r e c e p t o r ss ot h a ts t r e n g t ho fm e l a t o n i na sas y n c h r o -
nizing agent is reduced [126]. Moreover the input of neural
pathways involved in entrainment (synchronization) of the
central clock may become dysfunctional or less sensitive
during aging and even more so in AD [127]. In a large
multicentre trial only a nonsigniﬁcant trend to improvement
inthecircadianrhythmdisturbanceofADiswhentreatmentInternational Journal of Alzheimer’s Disease 5
Table 1: Clinical studies on melatonin eﬃcacy in AD.
Design Subjects
(M, F) Treatment Study’s
duration Measured Results Reference
Open-label
study
10 (6, 4)
demented
patients
3mg melatonin
p.o./daily at bed
time
3w e e k s
Daily logs of sleep and
wake quality completed by
caretakers
Seven out of ten dementia patients
having sleep disorders treated with
melatonin showed a signiﬁcant
decrease in sundowning and
reduced variability of sleep onset
time
[116]
Open-label
study
14 (8, 14)
AD patients
9mg melatonin
p.o./daily at bed
time
22 to 35
months
Daily logs of sleep and
wake quality completed by
caretakers.
Neuropsychological
assessment.
At the time of assessment, a
signiﬁcant improvement of sleep
quality was found. Sundowning was
not longer detectable in 12 patients
and persisted, although attenuated
in 2 patients. Clinically, the patients
exhibited lack of progression of the
cognitive and behavioral signs of
the disease during the time they
received melatonin.
[111]
Case report
Monozygotic
twins with
AD of 8
years
duration
One of the patients
was treated with
melatonin 9mg
p.o./daily at bed
time.
36
months
Neuropsychological
assessment.
Neuroimaging.
Sleep and cognitive function
severely impaired in the twin not
receiving melatonin as compared to
the melatonin-treated twin.
[112]
Open-label,
placebo-
controlled
trial
14AD
patients
6mg melatonin
p.o./daily at bed
time or placebo
4w e e k s
Daily logs of sleep and
wake quality completed by
caretakers. Actigraphy
The 7 AD patients receiving
melatonin showed a signiﬁcantly
reduced percentage of nighttime
activity compared to a placebo
group
[113]
Open-label
study
11 (3, 8) AD
patients
3mg melatonin
p.o./daily at bed
time
3w e e k s
Daily logs of sleep and
wake quality completed by
the nurses.
Analysis revealed a signiﬁcant
decrease in agitated behaviors in all
three shifts and a signiﬁcant
decrease in daytime sleepiness.
[117]
Open-label
study
45 (19, 26)
AD patients
6–9mg melatonin
p.o./daily at bed
time
4m o n t h s
Daily logs of sleep and
wake quality completed by
caretakers.
Neuropsychological
assessment.
Melatonin improved sleep and
suppressed sundowning, an eﬀect
seen regardless of the concomitant
medication employed to treat
cognitive or behavioral signs of AD.
[115]
Randomized
double blind
placebo
controlled
cross over
study
25AD
patients
6mgofslow
release melatonin
p.o. or placebo at
bed time
7w e e k s A c t i g r a p h y
Melatonin had no eﬀect on median
total time asleep, number of
awakenings, or sleep eﬃciency.
[118]
Double-
blind,
placebo-
controlled
study
20 (3, 17)
AD patients
Placebo or 3mg
melatonin
p.o./daily at bed
time
4w e e k s
Actigraphy.
Neuropsychological
assessment.
Melatonin signiﬁcantly prolonged
the sleep time and decreased activity
in the night. Cognitive function was
improved by melatonin.
[119]
Randomized,
placebo-
controlled
clinical trial
157 (70, 87)
AD patients
2.5mg slow-release
melatonin, or
10mg melatonin
or placebo at bed
time
2m o n t h s Actigraphy. Caregiver
ratings of sleep quality
Nonsigniﬁcant trends for increased
nocturnal total sleep time and
decreased wake after sleep onset
were observed in the melatonin
groups relative to placebo. On
subjective measures, caregiver
ratings of sleep quality showed
improvement in the 2.5mg
sustained-release melatonin group
relative to placebo.
[120]6 International Journal of Alzheimer’s Disease
Table 1: Continued.
Design Subjects
(M, F) Treatment Study’s
duration Measured Results Reference
Open-label
study
7 (4, 3) AD
patients
3mg melatonin
p.o./daily at bed
time
3w e e k s
Actigraphy.
Neuropsychological
assessment.
Complete remission of daynight
rhythm disturbances or
sundowning was seen in 4 patients,
with partial remission in other 2.
[114]
Randomized,
placebo-
controlled
study
17AD
patients
3mg melatonin
p.o./daily at bed
time (7 patients).
Placebo (10
patients)
2w e e k s
Actigraphy.
Neuropsychological
assessment.
In melatonin-treated group,
actigraphic nocturnal activity and
agitation showed signiﬁcant
reductions compared to baseline.
[121]
Randomized,
placebo-
controlled
study
50AD
patients
Morning light
exposure (2,500
lux, 1h) and 5mg
melatonin (n = 16)
or placebo
(n = 17) in the
evening. Control
subjects (n = 17)
received usual
indoor light
(150–200 lux).
10 weeks
Night time sleep variables,
day sleep time, day activity,
day:night sleep ratio, and
rest-activity parameters
were determined using
actigraphy.
Light treatment alone did not
improve night time sleep, daytime
wake, or rest-activity rhythm. Light
treatment plus melatonin increased
daytime wake time and activity
levels and strengthened the
rest-activity rhythm.
[122]
Case report
68-year-old
man with
AD who
developed
rapid eye
movement
(REM) sleep
behavior
disorder
5–10mg melatonin
p.o./daily at bed
time.
20
months Polysomnography Melatonin was eﬀective to suppress
REM sleep behavior disorder [123]
Randomized,
placebo-
controlled
study
41 (13, 28)
AD patients
Melatonin (8.5mg
immediate release
and 1.5mg
sustained release)
(N = 24) or
placebo (N = 17)
administered at
10:00P.M.
10 days Actigraphy.
There were no signiﬁcant eﬀects of
melatonin, compared with placebo,
on sleep, circadian rhythms, or
agitation.
[124]
was done using melatonin [120]. Because MT1 receptor
expression in the SCN is decreased it is certainly possible
that melatonin will be ineﬀective as a synchronizing agent
although it is possible that a higher dose of melatonin or a
more potent melatonin agonist such as ramelteon may be
useful. Another strategy could be exposure to bright light
[128] (see below).
5. Melatonin as a Therapeutic Agent for
Mild Cognitive Impairment
As outlined, melatonin acts at diﬀerent levels relevant to
the development and manifestation of AD. The antioxidant,
mitochondrial, and antiamyloidogenic eﬀects may be seen
as a possibility of interfering with the onset of the disease.
Therefore, early beginning of treatment may be decisive
[129].
Mild cognitive impairment (MCI) is an etiologically het-
erogeneoussyndromecharacterizedbycognitiveimpairment
shown by objective measures adjusted for age and education
in advance of dementia [130]. Approximately 12% of MCI
converts to AD or other dementia disorders every year. Since
MCI may represent prodromal A,D it should be adequately
diagnosed and treated. Indeed, the degenerative process in
AD brain starts 20–30 years before the clinical onset of the
disease [130]. During this phase, plaques and tangles loads
increaseandatacertainthresholdtheﬁrstsymptomappears.
As already mentioned, CSF melatonin levels decrease even
in preclinical stages when the patients do not manifest any
cognitive impairment (at Braak stages I-II), suggesting that
the reduction in CSF melatonin may be an early trigger and
marker for AD. Therefore, MCI could be an appropriate
moment for initiating any melatonin treatment aiming to
aﬀect progression of the disease. Studies on melatonin eﬀect
on MCI are summarized in Table 2.International Journal of Alzheimer’s Disease 7
Table 2: Clinical studies on melatonin eﬃcacy in MCI.
Design Subjects (M,F) Treatment Study’s
duration Measured Results Reference(s)
Double-blind,
placebo-
controlled,crossover
study
10 (4, 6)
patients with
mild cognitive
impairment
(MCI)
6mg melatonin
p.o./daily at bed
time
10 days
Actigraphy.
Neuropsychological
assessment.
Enhanced the rest-activity
r h y t h ma n di m p r o v e ds l e e p
quality (reduced sleep onset
latency and in the number of
transitions from sleep to
wakefulness Total sleep time
unaﬀected. The ability to
remember previously learned
items improved along with a
signiﬁcant reduction in
depressed mood.
[131]
Double-blind,
placebo-controlled
pilot study
26 individuals
with age-related
MCI
1mg melatonin
p.o. or placebo
at bed time
4w e e k s
Sleep questionnaire
and a battery of
cognitive tests at
baseline and at 4 weeks
Melatonin administration
improved reported morning
“restedness” and sleep latency
after nocturnal awakening and
also improved scores on the
California Verbal Learning
Test-interference subtest.
[132]
Open-label,
retrospective study
50 (13, 37) MCI
outpatients
25 had received
daily 3–9mg of
a fast-release
melatonin
preparation p.o.
at bedtime.
Melatonin was
given in
addition to the
standard
medication
9–18
months
Daily logs of sleep and
wake quality. Initial
and ﬁnal
neuropsychological
assessment.
Patients treated with
melatonin showed
signiﬁcantly better
performance in
neuropsychological
assessment. Abnormally high.
Beck Depression Inventory
scores decreased in
melatonin-treated patients,
concomitantly with an
improvement in wakefulness
and sleep quality.
[133]
Randomized, double
blind,
placebo-controlled
study
354 individuals
with age-related
cognitive decay
prolonged
release
melatonin
(Circadin, 2mg)
or placebo, 2h
before bedtime
3w e e k s
Leeds Sleep Evaluation
a n dP i t t s b u r g hS l e e p
Questionnaires,
Clinical Global
Improvement scale
score and quality of
life.
PR-melatonin resulted in
signiﬁcant and clinically
meaningful improvements in
sleep quality, morning
alertness, sleep onset latency,
and quality of life
[134]
Long-term,
double-blind,
placebo-controlled,
2 ×2f a c t o r i a l
randomized study
189 (19, 170)
individuals with
age-related
cognitive decay
Long-term daily
treatment with
whole-day
bright (1000
lux) or dim (300
lux) light.
Evening
melatonin
(2.5mg) or
placebo
administration
1t o3 . 5
years
Standardized scales for
cognitive and
noncognitive
symptoms, limitations
of activities of daily
living, and adverse
eﬀects assessed every 6
months.
Light attenuated cognitive
deterioration and also
ameliorated depressive
symptoms. Melatonin
shortened sleep onset latency
and increased sleep duration
but adversely aﬀected scores
for depression. The combined
treatment of bright light plus
melatonin showed the best
eﬀects.
[105]
Prospective,
randomized,
double-blind,
placebo-controlled,
study
22 (15, 7)
individuals with
age-related
cognitive decay
Participants
received 2
months of
melatonin (5mg
o.o./day) and 2
months of
placebo
2m o n t h s
Sleep disorders were
evaluated with the
Northside Hospital
Sleep Medicine
Institute (NHSMI) test.
Behavioral disorders
were evaluated with the
Yesavage Geriatric
Depression Scale and
Goldberg Anxiety
Scale.
Melatonin treatment
signiﬁcantly improved sleep
quality scores. Depression also
improved signiﬁcantly after
melatonin administration.
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The ﬁrst report on melatonin treatment of 10MCI
patients (6mg/day for 10 days) indicated that besides
enhancing the rest-activity rhythm and improved sleep
quality the ability to remember previously learned items
improved along with a signiﬁcant reduction in depressed
mood [131]. In another double-blind, placebo-controlled
pilot study performed in 26 individuals with age-related
MCI, the administration of 1mg melatonin or placebo at
bed time for 4 weeks resulted in improvement of sleep and
of scores on the California Verbal Learning Test-interference
subtest [132].
In a retrospective study of a group of 25 MCI patients
w h or e c e i v e dm e l a t o n i n( 3 – 9m gp e rd a y )f o r9t o1 8m o n t h s
in comparison to a similar group of 25MCI patients who
did not receive it [133], patients treated with melatonin
showed signiﬁcantly better performance in a number of
neuropsychological tests. Abnormally high Beck Depression
Inventory scores decreased in melatonin treated patients,
concomitantly with an improvement in wakefulness and
sleep quality. The results suggested that melatonin could be a
useful add-on drug for treating MCI in a clinic environment
[133]. A follow up of that study has now been completed on
a group of 35 MCI patients receiving melatonin for 9 to 24
months with essentially similar results [125].
A randomized controlled trial on the eﬀect of bright
light and melatonin on cognitive and noncognitive function
in elderly residents of group care facilities was published
[105]. The authors concluded that light has a beneﬁt in
improving some cognitive and noncognitive symptoms of
MCI which was ampliﬁed by the conjoint administration of
melatonin. In other two similar studies, one of them using
the prolonged release preparation of melatonin (Circadin)
recently approved by the European Medicines Agency,
melatonin resulted in signiﬁcant and clinically meaningful
improvements of sleep quality, morning alertness, sleep
onset latency and quality of life in old patients with mild
cognitive impairment [134, 135]. In these studies melatonin
treatment also improved mood. The evaluation of the
published data concerning melatonin treatment of MCI
that include 5 double blind, randomized placebo-controlled
trials, and 1 open-label retrospective study (N = 651)
all agreess in indicating that treatment with daily evening
melatonin improves sleep quality and cognitive performance
in MCI [125]( Table 2).
6. Use of Melatonin Agonist, Ramelteon in AD
As AD is associated with disturbed sleep/wake rhythms
and circadian rhythm disturbances, a melatonin agonist
with higher aﬃnity to melatonin MT1 and MT2 receptors
with a longer duration would theoretically be beneﬁcial in
tackling sleep-wake and circadian rhythm disturbances. In
this aspect, ramelteon, which is the ﬁrst melatonin receptor
agonist approved by FDA with activity on MT1 and MT2
receptors, should be considered [136, 137].
The chemical structure of ramelteon is: (S)-N-[2-
(1,6,7,8-tetrahydro-2Hindeno[5,4-b]furan-8-yl)ethyl] pro-
pionamide. This melatonin receptor agonist has a chem-
ical formula C16H21NO2 with a molecular weight 259.34.
Receptor binding studies indicated that ramelteon has high
selectivity for MT1 and MT2 receptors, with little aﬃnity
for quinone reductase 2 binding [138]. The selectivity of
ramelteon for MT1 has been found >1000-fold over that
of MT2 receptors. It is well known that melatonin exerts
its hypnotic eﬀects through the activation of the MT1 and
MT2 melatonin receptors [139]. Although both MT1 and
MT2 receptors are involved in the regulation of sleep, the
selectivity of MT1 receptors by ramelteon suggests that it
targets sleep onset more speciﬁcally than melatonin [140].
R a m e l t e o nh a sb e e nf o u n dt oh a v en oa ﬃnity for benzo-
diazepine (BZP), dopamine, opiate, or serotonin receptor
binding sites [138]. Hence ramelteon has advantages over
other hypnotic drugs in not causing rebound insomnia,
withdrawal symptoms, or dependence which is common
with the activation of BZP, opiate, or dopamine receptors.
On oral administration, ramelteon is rapidly absorbed
with a Tmax of less than 1 hour [141]. The absolute
bioavailability of the oral formulation of ramelteon is less
than2%(range0.5%to12%)[141].Itismetabolized mainly
in the liver via oxidation to hydroxyl and carbonyl groups
and then conjugated with glucuronide. CYP1A2 is the major
hepatic enzyme involved in ramelteon metabolism. Four
principal metabolites ramelteon, that is, M-I, M-II, M-III,
and M-IV, have been identiﬁed [141]. Among these, M-II
has been found to occur in much higher concentration with
systemic concentration being 20- to 100- fold greater than
ramelteon.
Ramelteon is rapidly excreted and its elimination is
signiﬁcantly higher in elderly than in younger adults [142].
The inﬂuence of age and gender on the pharmacokinetics
and pharmacodynamics of ramelteon has been evaluated in
healthy volunteers following the administration of a single
dose of 16mg of ramelteon. When compared to young
volunteers, ramelteon clearance was signiﬁcantly reduced in
elderly volunteers and its half life signiﬁcantly increased. No
signiﬁcant eﬀect of gender was observed [142]. The contri-
bution of ramelteon’s metabolites on the net pharmacologic
activity was also evaluated. Among the four metabolites
produced, the activity of M-II was to be about 30-fold lower
than that of ramelteon, but its exposure exceeds exposure to
ramelteon by a factor 30. It was thus suggested that M-II may
contribute to net clinical activity of ramelteon [142].
The subjective eﬃcacy of ramelteon was evaluated in
clinical trials consisting of 829 elderly outpatients with
chronic insomnia; 701 patients (128 patients discontinued)
were treated for a period of 5-weeks with 4mg and 8mg
ramelteon[143]. Patients in both ramelteon groups reported
signiﬁcant reductions in sleep onset latency (SOL) and
increases in total sleep time (TST). Continuation of this
study on 100 elderly patients established the eﬃcacy of
ramelteon in improving TST and decreasing SOL [144].
A number of studies have now established the eﬃcacy of
ramelteon in treating patients with chronic insomnia [145–
147].
Concerningthesafetyandadverseeﬀectswithramelteon,
in a double blind placebo controlled study of rebound
insomnia (sleep latency after treatment discontinuation)
Roth and co-workers [143] evaluated each of the 7 nightsInternational Journal of Alzheimer’s Disease 9
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Figure 1: Melatonergic agonists in AD. The multiple eﬀects of melatonin discussed in the text and the diﬀerent degree of overlap
(interrelations and mutual inﬂuences) are indicated by the respective intersections in the scheme.
of placebo run-out period. It was noted that during each of
the 7 nights, patients in both ramelteon treatment groups
(4mg/day and 8mg/day) maintained a similar or greater
reductioninsleeplatencyfrombaselineascomparedtothose
receiving placebo [143]. Withdrawal eﬀects, as assessed by
a BZP withdrawal symptom questionnaire, did not diﬀer
from the placebo group [143]. In another recent study it
was noted that ramelteon did not aﬀect alertness or the
ability to concentrate, indicating no next-morning residual
eﬀects [148]. The incidence of adverse eﬀects in ramelteon-
treated patients in a 5 week study was found to be similar to
that of placebo-treated patients. The adverse eﬀects included
mildgastrointestinaldisturbancesandnervoussystemeﬀects
suchas dizziness, headache, somnolence, depression, fatigue,
myalgia, and exacerbated eye pain [143].
Ramelteon not only has the potential in improving the
sleep quality of AD and other neurodegenerative patients
but can also oﬀer neuroprotection as well in AD [149]. As
ramelteon is a melatonin agonist with more potency and
longer duration of action, it could act more eﬃciently than
melatonin in its actions against neurotoxic eﬀectsinvolved in
the pathogenesis of AD.
To what extent ramelteon reproduces the nonre-
ceptor mediated eﬀects of melatonin is not known.
Ramelteon displays no relevant antioxidant capacity in
the ABTS radical cation assay, as compared to luzin-
dole or melatonin [150]. However, MT1/MT2 receptor-
mediated eﬀects on the upregulation of several antioxidant
enzymes by physiological concentration of melatonin [151]
such as glutathione peroxidase, glutathione reductase, γ-
glutamylcysteine synthase, glucose-6-phosphate dehydroge-
nase, hemoperoxidase/catalase, Cu,Zn- and Mn-superoxide
dismutases (reviewed in [152–155] can well give the basis
for the use of ramelteon in AD. Since there are extensive
data indicating a loss of melatonin receptors in AD patients,
including the cerebral cortex and pineal gland (MT1 and
MT2 receptors) [156], the hippocampus [157] and retina
[158] (MT2 receptors) and the cerebrovascular system [159],
and SCN [126, 128]( M T 1 receptors), the chances of
alleviating symptoms such as sundowning and disturbed
sleep by giving the MT1/MT2 receptor agonist may vanish
in late AD patients.
In addition, it has been suggested that melatonin and its
receptors participate in neurodevelopment and regulation of
neurotrophic factors [160]. In vitro studies have shown that
melatonin promotes the viability and neuronal diﬀerentia-
tion of neural stem cells and increases the production brain-
derived neurotrophic factor (BDNF) by acting through MT1
receptors [161]. In mouse cerebellar granule cells in culture
ramelteon increased the neural content of BDNF [162].
Therefore, if ramelteon treatment is capable of regulating
brain BDNF levels, it could be used as a possible therapeutic
agent in neurodegenerative diseases like AD for treating
symptoms other than sleep disturbances.
7. Concluding Remarks
As AD disease involves a complex physiopathology, it has
been suggested that monotherapy targeting early single steps
in this complex cascade process may not be of much help
[149]. Pleiotrophic drugs that can act independently by
diﬀerent routes including antioxidant, antiinﬂammatory,
and antiamyloid eﬀects would be much beneﬁcial in the
treatment of AD and other neurodegenerative disorders.
Available evidence indicates suppression of GSK-3β over-
activity; neuroinﬂammation and mitochondrial impairment
are some of the combined strategies required in AD.
Melatonin is a pleiotropic molecule with antioxidant,
antiinﬂammatory and antinitridergic properties [56, 154,
163]. It has also a role in sleep induction, and this is
important in view that sleep deprivation is one of the
cardinal features seen in AD and other neurodegenera-
tive diseases. Sleep deprivation is associated with GSK-
3β activation [164], altered proteosomal processing [165],10 International Journal of Alzheimer’s Disease
oxidative damage [166], impaired mitochondrial integrity
and function [167], and neurodegenerative inﬂammation
[168]. Therefore, improvement of insomnia in neurode-
generative conditions and particularly in AD is a good
practicalapproachforarrestingtheprogressionofthedisease
(Figure 1).
Melatonin and particularly ramelteon can be greatly
beneﬁcial in preventing the insomnia-induced damage of
neuronal cells and can be of therapeutic value in treating
AD. Owing to its potent eﬀect on MT1 and MT2 recep-
tors, ramelteon activates sleep onset by inﬂuencing the
hypothalamic “sleep switch” downstream from the SCN
more eﬃciently than melatonin itself [35]. Multicenter,
placebo-controlled clinical trials using ramelteon are needed
to prove the eﬃcacy of this drug in arresting the progression
or prevention of AD or remission in the early stages of AD
such as MCI.
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